IL6 and periodontitis: We aimed to assess the influence of the IL-6 receptor inhibitor on periodontal status in active RA associated with periodontitis, assuming that TCZ might be able not only to improve clinical and biochemical RA-related parameters but also to ameliorate chronic periodontitis as a result of decreased IL-6 in the periodontal microenvironment via declining systemic inflammation.